1 March 2018 - Price is a key factor for cost effectiveness.

Since 1999 NICE has been scrutinising the clinical and cost effectiveness of medicines and other health technologies. NICE committees draw on cost effectiveness thresholds to help them make their recommendations, and those recommendations include a legal requirement for the NHS in England to fund, or not to, as the case may be. 

NICE is one of only a handful of health technology assessment agencies that has an explicit threshold range. That said, NICE doesn’t say what the price should be in order to hit its threshold.

Read Pharmaphorum article